 Good Morning! 
Yesterday's 200%+ gainer ran on news that I haven't seen move stocks in over a year…
So when I saw Veru Inc.'s (NASDAQ: VERU) premarket spike and Breaking News Chat alert, I admit I underestimated it.
But now that macro headlines have changed and we've had this massive spiker — will COVID penny stocks be great again?
Or is VERU just another crappy one-and-done biotech? Read on to find out what I think could be next for VERU and the entire biotech sector.
Before you trade any biotech stock — click here to learn the biggest mistake you MUST avoid! What Sparked a 200% Gain? Even taking a small piece of this Breaking News Chat winner is a great gain for a small account. We haven't seen these kinds of gains in a while…  VERU chart: 1-day, 1-minute candle — courtesy of StocksToTrade.com But VERU wasn't my top watch yesterday...
It has a large float, the volume was just OK, and I didn't love the news.
As traders, we look for patterns. And based on recent history, COVID news hasn't moved stocks in about a year. So I wasn't overly excited about it.
But you have to respect how VERU played the game…
Management pumped out a COVID PR as worldwide headlines shifted from the Russia-Ukraine crisis to the lockdowns in China.
It's scary news — and scary moves stocks.
But most of the lockdown headlines seem to focus more on the impacts to supply chains and manufacturing.
So was a 200% gain on COVID news warranted? The thing is, it's not just about the news…
As day traders we want to take advantage of several factors:
And big runners like VERU are how hot sectors get started. That's why I know my top watch for the rest of this week… HOT Biotechs Seeing a 200% gainer on COVID news means all the degenerate traders will be looking for the next VERU.
It could be another COVID penny stock or another stock in the biotech sector.
As an example, look at Altamira Therapeutics Ltd. (NASDAQ: CYTO) yesterday morning...
It also announced COVID-related news. It had just made new daily lows when VERU broke through the $8 high of the day…
 CYTO chart: 1-day, 1-minute candle — courtesy of StocksToTrade.com But COVID isn't the only news moving biotechs recently…
Yesterday, Hoth Therapeutics, Inc. (NASDAQ: HOTH) gained over 100% in premarket after announcing its mRNA therapeutic reduced cancer cell growth. It was a top watch for a morning dip and rip. That plan kept me and SteadyTrade Team members safe.
But mRNA technology is a buzzword lately. And HOTH is still a big percent gainer with news and high volume. So it's on watch if it hangs around.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is another hot biotech. If you follow my weekly watchlist, you know why I like it.
PHIO was my top watch yesterday. I didn't get the move I wanted, but the stock held up and traded sideways all day. It's a great candidate for a potential day-three surge today.
Those are just some of the moves I'll watch for. But remember the number-one rule about trading biotechs… How to Trade Biotechs You hear me say this a lot — biotech stocks are day trades only.
Why?
Because they're super sketchy. So many biotechs only trade publicly because selling stock is how they raise capital.
And you must always be wary of potential offerings.
If you want the safest game plans every trading day — join the SteadyTrade Team.
I break down all the biggest daily percent gainers in my twice-daily webinars.
Hope to see you in the chat room!
Have a great day. See you back here tomorrow.
Tim Bohen Lead Trainer, StocksToTrade
sponsored Our goal is to make you 1% better every day. Come LIVE trade alongside a pro trader, 2x a day, every single trading day of the year.
sponsored
 Hey! Matt Monaco here…
This week, I'm going live to reveal my #1 crypto trade to make right now.
If you've been watching what's been happening in the crypto market…
And you think you're too late to the party…
You're dead wrong.
Recommended Membership Gifts
ACCESS NOW: Click to activate these complimentary membership gifts and receive daily market intel.
  
(As an Amazon Associate, we earn from qualifying purchases.)
13809 Research Boulevard, Suite 500, Austin, TX 78750
*Please note that these kinds of trading results are not typical. Most traders lose money. It takes years of dedication, hard work, and discipline to learn how to trade, and individual results will vary. Trading is inherently risky. Before making any trades, remember to do your due diligence and never risk more than you can afford to lose.
This is for informational purposes only as StocksToTrade is not registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund.
StocksToTrade cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing.
StocksToTrade in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, StocksToTrade accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.
Copyright © StocksToTrade.com |
No comments:
Post a Comment